Literature DB >> 3500184

Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells.

W B Graninger1, M Seto, B Boutain, P Goldman, S J Korsmeyer.   

Abstract

We examined the expression of the Bcl-2 gene at chromosome segment 18q21, that is translocated into the Ig heavy chain gene locus in t(14;18) bearing lymphomas. Bcl-2, while B cell associated, is expressed in a variety of hematopoietic lineages including T cells. Bcl-2 mRNA levels are high during pre-B cell development, the time at which the t(14;18) translocation occurs, but are down regulated with maturation. Like certain other oncogenes, Bcl-2 is quiescent in resting B cells but up-regulated with B cell activation. Mature B cell lymphomas with a t(14;18) have log-folds more mRNA than matched counterparts without the translocation. A sensitive S1 protection assay revealed that all transcripts in t(14;18) B cells were Bcl-2-Ig fusion mRNAs and originated from the translocated allele. Thus, there is a marked deregulation of Bcl-2 when it is introduced into the Ig locus in t(14;18) lymphomas.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500184      PMCID: PMC442413          DOI: 10.1172/JCI113235

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Mechanism of the t(14;18) chromosomal translocation: structural analysis of both derivative 14 and 18 reciprocal partners.

Authors:  A Bakhshi; J J Wright; W Graninger; M Seto; J Owens; J Cossman; J P Jensen; P Goldman; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

2.  K562--a human erythroleukemic cell line.

Authors:  L C Andersson; K Nilsson; C G Gahmberg
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

Review 3.  Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma.

Authors:  K Nilsson; G Klein
Journal:  Adv Cancer Res       Date:  1982       Impact factor: 6.242

4.  RNA processing errors in patients with beta-thalassemia.

Authors:  T J Ley; N P Anagnou; G Pepe; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

5.  Identification of the constant chromosome regions involved in human hematologic malignant disease.

Authors:  J D Rowley
Journal:  Science       Date:  1982-05-14       Impact factor: 47.728

6.  The role of gene dosage and genetic transpositions in carcinogenesis.

Authors:  G Klein
Journal:  Nature       Date:  1981-11-26       Impact factor: 49.962

7.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma.

Authors:  J J Yunis; M M Oken; M E Kaplan; K M Ensrud; R R Howe; A Theologides
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

8.  Isolation and characterization of full-length cDNA clones for human alpha-, beta-, and gamma-actin mRNAs: skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed.

Authors:  P Gunning; P Ponte; H Okayama; J Engel; H Blau; L Kedes
Journal:  Mol Cell Biol       Date:  1983-05       Impact factor: 4.272

9.  Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.

Authors:  G M Lenoir; J L Preud'homme; A Bernheim; R Berger
Journal:  Nature       Date:  1982-07-29       Impact factor: 49.962

10.  Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins.

Authors:  S J Korsmeyer; A Arnold; A Bakhshi; J V Ravetch; U Siebenlist; P A Hieter; S O Sharrow; T W LeBien; J H Kersey; D G Poplack; P Leder; T A Waldmann
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

View more
  66 in total

Review 1.  One path to cell death in the nervous system.

Authors:  J Glasgow; R Perez-Polo
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 2.  Detection of BCL2 rearrangements in follicular lymphoma.

Authors:  Jon C Aster; Janina A Longtine
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

3.  Meiotic recombination between yeast artificial chromosomes yields a single clone containing the entire BCL2 protooncogene.

Authors:  G A Silverman; E D Green; R L Young; J I Jockel; P H Domer; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  The BCL-2 5' untranslated region contains an RNA G-quadruplex-forming motif that modulates protein expression.

Authors:  Ramla Shahid; Anthony Bugaut; Shankar Balasubramanian
Journal:  Biochemistry       Date:  2010-09-28       Impact factor: 3.162

5.  Triplex forming oligonucleotide targeted to 3'UTR downregulates the expression of the bcl-2 proto-oncogene in HeLa cells.

Authors:  C Shen; A Buck; G Mehrke; B Polat; H Gross; M Bachem; S Reske
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

Review 6.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

7.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

8.  Microarray analysis of B-cell lymphoma cell lines with the t(14;18).

Authors:  Ryan S Robetorye; Sandra D Bohling; John W Morgan; G Chris Fillmore; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

9.  Bcl-2 protein expression during murine development.

Authors:  D V Novack; S J Korsmeyer
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

10.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.